Skip to content

Radiation safety study of ultrasound-combined CT-guided pulsed radio frequency therapy for neuropathic neuralgia in dorsal root ganglia: Clinical validation of reducing the number of CT scans based on pre-positioning techniques

Radiation safety study of ultrasound-combined CT-guided pulsed radio frequency therapy for neuropathic neuralgia in dorsal root ganglia: Clinical validation of reducing the number of CT scans based on pre-positioning techniques

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110751
Enrollment
Unknown
Registered
2025-10-20
Start date
2025-10-20
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuropathic pain

Interventions

control group:Simple CT guidance
test group:Ultrasound pre-positioning + CT verification

Sponsors

Affiliated Hospital of Jiangsu University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age 18~90 years old, gender is not limited; 2. Meet the diagnostic criteria for NP as defined by the International Association for the Study of Pain (IASP), and be clinically and imaging (e.g., MRI/CT) proven to be DRG-related NP (e.g., postherpetic neuralgia, lumbar disc herniation with radicular pain, lumbar postoperative pain syndrome, etc.); 3. Pain duration >= 1 month; 4. resting visual analogue score (VAS) >= 4; 5. Ineffective conservative treatment (e.g., medication, physiotherapy, etc.) (pain relief <50%); 6. Understand and co-operate with the pain assessment and treatment process; 7. Voluntarily participate in the study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. in the contraindications to pulsed radiofrequency therapy (e.g. internal implantation of electronic devices such as pacemakers, defibrillators, etc.); 2. in coagulation disorders (prothrombin time >1.2 times the normal range, activated partial thromboplastin time >1.2 times the normal range or platelet count 160 mmHg or diastolic blood pressure >100 mmHg); 5. Mental illness (e.g. schizophrenia, major depressive disorder) or cognitive impairment that prevents co-operation with treatment and assessment; 6. Pregnant or breastfeeding women; 7. History of previous radiofrequency treatment or surgery for targeted segmental DRG; 8. allergy to local anaesthetics (e.g. lidocaine) or contrast media; 9. Participants in other concurrent clinical studies.

Design outcomes

Primary

MeasureTime frame
CT radiation dose;Number of punctures;

Secondary

MeasureTime frame
total operation time;pain relief rate;adverse reactions;

Countries

China

Contacts

Public ContactLi Chunye

Affiliated Hospital of Jiangsu University

372098744@qq.com+86 132 1839 8733

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026